Company Update (NASDAQ:VRTX): Vertex Announces Significant Progress in Its Development Efforts to Treat the Cause of Cystic Fibrosis in the Vast Majority of People with the Disease

[Business Wire] – Vertex Pharmaceuticals Incorporated today announced significant progress in its development efforts to treat the underlying cause of cystic fibrosis for the vast majority of people with the disease. Read more . . . → Read More: Company Update (NASDAQ:VRTX): Vertex Announces Significant Progress in Its Development Efforts to Treat the Cause of Cystic Fibrosis in the Vast Majority of People with the Disease Similar Articles: Company Update: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Vertex to Announce Second Quarter 2015 Financial Results on July 29 Market Update: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Vertex Announces Data Presentations at European Cystic Fibrosis Society (ECFS) Conference Company Update: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary Diseases